AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class antibody-drug conjugate (ADC) telisotuzumab-vedotin, which targets c-Met protein-overexpressing, EGFR-wild-type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial results showed an overall response rate (ORR) of 35% in patients with high c-Met levels and 23% in those with intermediate levels. The median duration of response (DOR) was 9 months for the high c-Met group and 7.2 months for the intermediate group, with median overall survival (OS) at 14.6 months and 14.2 months, respectively. The safety profile observed was in line with previous studies.
AbbVie plans to present these results to global regulatory authorities with the aim of securing an accelerated approval for the c-Met protein-directed medicine, which is currently under accelerated review in several markets. The drug candidate is also the subject of a late-stage study in patients with previously treated c-Met protein-overexpressing, EGFR-wild-type, nonsquamous NSCLC.- Flcube.com
